UCB (OTCMKTS:UCBJY) Shares Down 9.3% – Time to Sell?

UCB SA (OTCMKTS:UCBJY)’s share price fell 9.3% during mid-day trading on Friday . The company traded as low as $129.55 and last traded at $129.55. Approximately 1,261 shares changed hands during mid-day trading, a decline of 97% from the average daily volume of 36,031 shares. The stock had previously closed at $142.88.

Analysts Set New Price Targets

Several equities research analysts have commented on the stock. Barclays downgraded shares of UCB from a “strong-buy” rating to a “hold” rating in a report on Monday, June 15th. Zacks Research raised shares of UCB from a “strong sell” rating to a “hold” rating in a research report on Monday, July 6th. Finally, Jefferies Financial Group upgraded shares of UCB to a “moderate sell” rating in a research note on Monday, June 22nd. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold”.

UCB Trading Up 2.8%

The business’s fifty day moving average price is $143.74 and its 200-day moving average price is $147.55. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.38 and a quick ratio of 1.04.

UCB Company Profile

UCB is a global biopharmaceutical company founded in Belgium in 1928, specializing in the discovery and development of therapies for severe diseases in the fields of neurology and immunology. Headquartered in Brussels, UCB leverages nearly a century of scientific expertise to address areas of high unmet medical need, with a focus on chronic conditions such as epilepsy, Parkinson’s disease, rheumatoid arthritis and Crohn’s disease.

The company’s commercial portfolio includes key branded medicines such as CIMZIA (certolizumab pegol) for inflammatory disorders, VIMPAT (lacosamide) for the treatment of partial-onset seizures in epilepsy, and NEUPRO (rotigotine transdermal system) for Parkinson’s disease and restless legs syndrome.